Torrent Pharmaceuticals Limited
TORNTPHARM · Pharma · NSE
₹4,153
Current Market Price
Fair Value (DCF)
₹2,127
Margin of Safety
-48.8%
Updated 5h ago
YieldIQ Score
28/100
Piotroski F-Score
7/9
Economic Moat
Moderate
Confidence
45%
ROE
25.2%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹1.41 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
28.5%
Return on capital employed
EV / EBITDA
35.7×
Enterprise multiple
Debt / EBITDA
0.7×
Leverage vs earnings
Interest Coverage
11.6×
EBIT covers interest
Current Ratio
1.19×
Short-term liquidity
Asset Turnover
0.81×
Revenue per ₹ of assets
Revenue CAGR (3Y)
—
3-year revenue growth
Revenue CAGR (5Y)
9.4%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹4,152.5
Bear case
₹1,257.21
MoS -230.3%
Base case
₹2,126.93
MoS -95.2%
Bull case
₹2,927.51
MoS -41.8%
Ratio Trends
TORNTPHARM · last 8 annual periods
ROE
25.2%
ROCE
34.5%
Operating Margin
—
Debt / Equity
0.42×
PE
181.3×
EV / EBITDA
18.9×
Historical Financials
TORNTPHARM · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹8005 Cr | ₹8508 Cr | ₹2491 Cr | ₹2745 Cr | ₹11.3K Cr | +9.0% |
| EBITDA | — | ₹2141 Cr | ₹2881 Cr | ₹3500 Cr | ₹3719 Cr | +14.8% |
| EBIT | ₹1884 Cr | ₹1481 Cr | ₹540 Cr | ₹711 Cr | — | -21.6% |
| PAT | ₹1252 Cr | ₹777 Cr | ₹287 Cr | ₹449 Cr | ₹1911 Cr | +11.2% |
| EPS (diluted) | ₹73.98 | ₹0.00 | ₹8.48 | ₹13.27 | — | -34.9% |
| CFO | ₹2011 Cr | ₹1803 Cr | ₹2368 Cr | ₹3266 Cr | ₹2585 Cr | +6.5% |
| CapEx | — | — | — | — | ₹-612 Cr | — |
| FCF | — | — | — | — | ₹1973 Cr | +0.0% |
| Total Assets | — | ₹13.1K Cr | ₹15.0K Cr | ₹15.1K Cr | ₹15.0K Cr | +3.4% |
| Total Debt | — | — | ₹2801 Cr | ₹2334 Cr | ₹3202 Cr | +3.4% |
| Shareholders' Equity | — | — | ₹6198 Cr | ₹6856 Cr | ₹7591 Cr | +5.2% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
TORNTPHARM vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| DIVISLAB DIVISLAB | — | — | Pending | 14.6% | 0.8× |
| LUPIN Lupin Limited | +16.1% | 37 | Undervalued | 19.0% | — |
| DRREDDY Dr. Reddy's Laboratories Limited | +73.3% | 63 | Undervalued | 16.8% | 16.8× |
| CIPLA Cipla Limited | +43.1% | 66 | Data Limited | 16.9% | 22.1× |
| ZYDUSLIFE Zydus Lifesciences Limited | +47.7% | 45 | Data Limited | 17.2% | — |
Click a ticker to view its fair-value analysis.
Dividend History
18 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹142.50/sh
Last payout
2026-02-18
₹29.00
Peak payout
₹29.00
Trailing yield
0.84%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Torrent Pharmaceuticals Limited (TORNTPHARM.NS) trades at 4152.50 vs a model fair value of 2126.93, a gap of -48.8%. Piotroski F-score: 7...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of TORNTPHARM →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for TORNTPHARM →
Compare
Head-to-head with peers
Compare TORNTPHARM side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse TORNTPHARMNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.